Osteoarthritis Year in Review 2016: biomarkers (biochemical markers)

详细信息    查看全文

• 作者：A. Mobasheri^&dagger ; ; ^&Dagger ; ; ^&sect ; ; ^a ; ^{a.mobasheri@surrey.ac.uk} ; A.-C. Bay-Jensen^‖ ; W.E. van Spil^¶ ; ; J. Larkin^# ; M.C. Levesque^&dagger ; &dagger ;
• 关键词：Osteoarthritis ; Cartilage ; Synovium ; Biomarker ; Biochemical marker ; Assay
• 刊名：Osteoarthritis and Cartilage
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：25
• 期：2
• 页码：199-208
• 全文大小：798 K
• 卷排序：25

文摘

The aim of this “Year in Review” article is to summarize and discuss the implications of biochemical marker related articles published between the Osteoarthritis Research Society International (OARSI) 2015 Congress in Seattle and the OARSI 2016 Congress in Amsterdam.MethodsThe PubMed/MEDLINE bibliographic database was searched using the combined keywords: ‘biomarker’ and ‘osteoarthritis’. The PubMed/MEDLINE literature search was conducted using the Advanced Search Builder function (http://www.ncbi.nlm.nih.gov/pubmed/advanced).ResultsOver two hundred new biomarker-related papers were published during the literature search period. Some papers identified new biomarkers whereas others explored the biological properties and clinical utility of existing markers. There were specific references to several adipocytokines including leptin and adiponectin. ADAM Metallopeptidase with Thrombospondin Type 1 motif 4 (ADAMTS-4) and aggrecan ARGS neo-epitope fragment (ARGS) in synovial fluid (SF) and plasma chemokine (CeC motif) ligand 3 (CCL3) were reported as potential new knee biomarkers. New and refined proteomic technologies and novel assays including a fluoro-microbead guiding chip (FMGC) for measuring C-telopeptide of type II collagen (CTX-II) in serum and urine and a novel magnetic nanoparticle-based technology (termed magnetic capture) for collecting and concentrating CTX-II, were described this past year.ConclusionThere has been steady progress in osteoarthritis (OA) biomarker research in 2016. Several novel biomarkers were identified and new technologies have been developed for measuring existing biomarkers. However, there has been no “quantum leap” this past year and identification of novel early OA biomarkers remains challenging. During the past year, OARSI published a set of recommendations for the use of soluble biomarkers in clinical trials, which is a major step forward in the clinical use of OA biomarkers and bodes well for future OA biomarker development.